UPSC : Editorial Analysis: Sickle Cell Disease in India: A Public Health Challenge
Kartavya Desk Staff
*General Studies-2; Topic: Issues relating to development and management of Social Sector/Services relating to Health, Education, Human Resources.*
Introduction
• In 2023, Prime Minister Narendra Modi launched the National Sickle Cell Anaemia Elimination Mission, targeting the elimination of sickle cell disease (SCD) as a public health issue by 2047.
• This mission reflects the government’s focus on combating a genetic disorder that affects over 1 million people in India.
Background
• Sickle Cell Disease (SCD): A genetic disorder causing crescent-shaped, rigid red blood cells that block blood flow. Leads to complications like severe pain, swelling, anemia, infections, and organ damage (heart, liver, kidneys). Lifespan of affected individuals is significantly shortened, averaging 40 years.
• A genetic disorder causing crescent-shaped, rigid red blood cells that block blood flow.
• Leads to complications like severe pain, swelling, anemia, infections, and organ damage (heart, liver, kidneys).
• Lifespan of affected individuals is significantly shortened, averaging 40 years.
• Prevalence: Most common among tribal populations in states like Odisha, Jharkhand, Chhattisgarh, Madhya Pradesh, and Maharashtra.
• Most common among tribal populations in states like Odisha, Jharkhand, Chhattisgarh, Madhya Pradesh, and Maharashtra.
Challenges
• Low Treatment Access: Only 18% of affected individuals receive consistent treatment.
• Only 18% of affected individuals receive consistent treatment.
• Misdiagnosis and Stigma: Tribal populations often rely on traditional healers, leading to misdiagnosis. Delays in proper diagnosis exacerbate complications.
• Tribal populations often rely on traditional healers, leading to misdiagnosis.
• Delays in proper diagnosis exacerbate complications.
• Medicinal Access and Treatment Adherence: Despite Hydroxyurea being on India’s essential medicines list, its supply is inconsistent. Patients face challenges like irregular availability and long travel distances to health facilities.
• Despite Hydroxyurea being on India’s essential medicines list, its supply is inconsistent.
• Patients face challenges like irregular availability and long travel distances to health facilities.
• Poor Vaccination Coverage: Vaccines that could reduce infections in SCD patients are underutilized. Lack of vaccinations increases the frequency of infections and related complications.
• Vaccines that could reduce infections in SCD patients are underutilized.
• Lack of vaccinations increases the frequency of infections and related complications.
Economic Impact
• Burden on Families: Chronic health issues reduce productivity and workforce participation. Recurrent hospitalizations and long-term treatments impose financial strain, particularly in economically vulnerable regions.
• Chronic health issues reduce productivity and workforce participation.
• Recurrent hospitalizations and long-term treatments impose financial strain, particularly in economically vulnerable regions.
• National Economic Strain: SCD affects economic output due to the loss of productive years of affected individuals.
• SCD affects economic output due to the loss of productive years of affected individuals.
Key Stakeholders
• Central and State Governments: Crucial for funding, policy creation, and healthcare delivery.
• Crucial for funding, policy creation, and healthcare delivery.
• Healthcare Professionals: Screening, diagnosis, and consistent treatment are dependent on skilled practitioners.
• Screening, diagnosis, and consistent treatment are dependent on skilled practitioners.
• Tribal Communities: Awareness and education are necessary to overcome stigma and mistrust.
• Awareness and education are necessary to overcome stigma and mistrust.
• Philanthropists and Civil Society: Can enhance outreach, funding, and healthcare infrastructure.
• Can enhance outreach, funding, and healthcare infrastructure.
• Researchers and Pharmaceutical Companies: Essential for developing affordable treatments and advancing therapies like gene therapy.
• Essential for developing affordable treatments and advancing therapies like gene therapy.
Government Schemes and Initiatives
• National Sickle Cell Anaemia Elimination Mission: Comprehensive strategy for screening, diagnosis, and treatment with an aim to eliminate SCD by 2047.
• Comprehensive strategy for screening, diagnosis, and treatment with an aim to eliminate SCD by 2047.
• Nationwide Screening Programmes: Identifying carriers of the sickle cell trait to enable early detection.
• Identifying carriers of the sickle cell trait to enable early detection.
• Inclusion of Hydroxyurea: Added to India’s essential medicines list to improve treatment access.
• Added to India’s essential medicines list to improve treatment access.
• Research in Gene Therapy: Although not widely available, gene therapy holds promise for future SCD treatment.
• Although not widely available, gene therapy holds promise for future SCD treatment.
International Best Practices
• Newborn Screening: Countries like the USA and UK have implemented nationwide newborn screening programs.
• Countries like the USA and UK have implemented nationwide newborn screening programs.
• Centers of Excellence: Specialized centers focus on interdisciplinary management of SCD.
• Specialized centers focus on interdisciplinary management of SCD.
• Public Awareness Campaigns: Extensive campaigns in countries like the USA educate the public about SCD.
• Extensive campaigns in countries like the USA educate the public about SCD.
• Multidisciplinary Care Models: Involve hematologists, psychologists, nutritionists, and social workers to provide holistic care.
• Involve hematologists, psychologists, nutritionists, and social workers to provide holistic care.
• Genetic Counseling Services: Help families understand the hereditary nature of the disease and make informed reproductive choices.
• Help families understand the hereditary nature of the disease and make informed reproductive choices.
Way Forward
• Reducing Stigma: Awareness campaigns, similar to those for HIV and polio, can address stigma and misinformation.
• Awareness campaigns, similar to those for HIV and polio, can address stigma and misinformation.
• Expanding Newborn Screening: Prioritize high-risk areas for early detection of sickle cell traits.
• Prioritize high-risk areas for early detection of sickle cell traits.
• Ensuring Drug Access: Regular and consistent supply of Hydroxyurea at local healthcare centers is essential.
• Regular and consistent supply of Hydroxyurea at local healthcare centers is essential.
• Improving Vaccination Rates: Ensure all known patients receive vaccinations to reduce infections.
• Ensure all known patients receive vaccinations to reduce infections.
• Strengthening Tribal Healthcare: Enhance funding and infrastructure in tribal areas, coupled with trust-building initiatives.
• Enhance funding and infrastructure in tribal areas, coupled with trust-building initiatives.
• Advancing Research: Invest in affordable gene therapy and novel treatments to manage the disease.
• Invest in affordable gene therapy and novel treatments to manage the disease.
Conclusion
• The National Sickle Cell Anaemia Elimination Mission represents a strong step toward addressing SCD in India.
• Achieving the 2047 goal requires a multi-pronged approach involving diagnosis, treatment, awareness, and research, with active participation from all stakeholders.
Practice Question
India bears the world’s second-largest burden of sickle cell disease, which predominantly affects tribal populations across various states. Analyze the key challenges in diagnosis, treatment adherence, and healthcare access for sickle cell patients. How can international best practices be adapted to address these challenges in India? (250 words)